A prospective study of tea drinking temperature and risk of esophageal squamous cell carcinoma.
Iran
esophageal cancer
hot beverages
risk factor
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
01 01 2020
01 01 2020
Historique:
received:
08
11
2018
revised:
16
01
2019
accepted:
05
02
2019
pubmed:
21
3
2019
medline:
15
2
2020
entrez:
21
3
2019
Statut:
ppublish
Résumé
Previous studies have reported an association between hot tea drinking and risk of esophageal cancer, but no study has examined this association using prospectively and objectively measured tea drinking temperature. We examined the association of tea drinking temperature, measured both objectively and subjectively at study baseline, with future risk of esophageal squamous cell carcinoma (ESCC) in a prospective study. We measured tea drinking temperature using validated methods and collected data on several other tea drinking habits and potential confounders of interest at baseline in the Golestan Cohort Study, a population-based prospective study of 50,045 individuals aged 40-75 years, established in 2004-2008 in northeastern Iran. Study participants were followed-up for a median duration of 10.1 years (505,865 person-years). During 2004-2017, 317 new cases of ESCC were identified. The objectively measured tea temperature (HR 1.41, 95% CI 1.10-1.81; for ≥60°C vs. <60°C), reported preference for very hot tea drinking (HR 2.41, 95% CI 1.27-4.56; for "very hot" vs. "cold/lukewarm"), and reported shorter time from pouring tea to drinking (HR 1.51, 95% CI 1.01-2.26; for <2 vs. ≥6 min) were all associated with ESCC risk. In analysis of the combined effects of measured temperature and amount, compared to those who drank less than 700 ml of tea/day at <60°C, drinking 700 mL/day or more at a higher-temperature (≥60°C) was consistently associated with an about 90% increase in ESCC risk. Our results substantially strengthen the existing evidence supporting an association between hot beverage drinking and ESCC.
Identifiants
pubmed: 30891750
doi: 10.1002/ijc.32220
pmc: PMC7477845
mid: NIHMS1625850
doi:
Substances chimiques
Tea
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
18-25Subventions
Organisme : Cancer Research UK
ID : 10119
Pays : United Kingdom
Organisme : Intramural NIH HHS
ID : Z01 CP000185
Pays : United States
Organisme : Cancer Research UK
ID : C20/A5860
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2019 UICC.
Références
Arch Iran Med. 2012 Apr;15(4):196-200
pubmed: 22424034
BMC Cancer. 2018 Mar 1;18(1):236
pubmed: 29490609
Am J Clin Nutr. 2012 Nov;96(5):1056-63
pubmed: 23053557
BMJ. 2009 Mar 26;338:b929
pubmed: 19325180
Medicine (Baltimore). 2017 Dec;96(50):e9325
pubmed: 29390400
IARC Monogr Eval Carcinog Risks Hum. 2010;92:1-853
pubmed: 21141735
Int J Epidemiol. 2010 Feb;39(1):52-9
pubmed: 19332502
Cancer Lett. 1995 Jun 29;93(1):17-48
pubmed: 7600541
Oncol Rep. 2003 Mar-Apr;10(2):421-6
pubmed: 12579283
Int J Cancer. 2005 Jan 20;113(3):456-63
pubmed: 15455378
J Agric Food Chem. 2004 Dec 29;52(26):8268-71
pubmed: 15612828
Am J Prev Med. 2015 Dec;49(6):952-60
pubmed: 26590941
Asia Pac J Clin Nutr. 2010;19(4):564-71
pubmed: 21147719
Eur J Clin Nutr. 2006 Aug;60(8):971-7
pubmed: 16465196
Br J Cancer. 2005 Jan 17;92(1):176-81
pubmed: 15597107
Gut. 2010 Sep;59(9):1178-83
pubmed: 20584779
Int J Cancer. 2013 Jun 15;132(12):2738-47
pubmed: 23175176
Eur J Cancer. 2009 Dec;45(18):3156-65
pubmed: 19800783
Am J Clin Nutr. 2004 Dec;80(6):1558-64
pubmed: 15585768
Int J Cancer. 2014 Sep 15;135(6):1470-9
pubmed: 24535727
Am J Physiol. 1999 Jun;276(6):G1322-30
pubmed: 10362635
Gastroenterology. 2018 Jan;154(2):360-373
pubmed: 28823862
Br J Cancer. 2004 Apr 5;90(7):1402-6
pubmed: 15054463
Eur J Cancer. 2010 Jul;46(10):1873-81
pubmed: 20395127
J Epidemiol. 2006 Sep;16(5):185-92
pubmed: 16951537
Br J Cancer. 1979 Mar;39(3):293-309
pubmed: 465299
J Dig Dis. 2017 Aug;18(8):431-444
pubmed: 28749599
Lancet Oncol. 2016 Jul;17(7):877-878
pubmed: 27318851
Int J Cancer. 2009 Aug 1;125(3):491-524
pubmed: 19415743
Tob Control. 2017 Nov;26(6):674-682
pubmed: 27872345
Anticancer Res. 2005 Jan-Feb;25(1B):425-8
pubmed: 15816606
Ann Intern Med. 2018 Apr 3;168(7):489-497
pubmed: 29404576
Exp Mol Pathol. 2016 Apr;100(2):325-31
pubmed: 26899552
J Natl Cancer Inst. 1977 Oct;59(4):1127-38
pubmed: 561853
Nutr Cancer. 2008;60(2):216-21
pubmed: 18444153
Cancer Lett. 1989 Oct;47(3):179-85
pubmed: 2635642
Asian Pac J Cancer Prev. 2011;12(1):229-33
pubmed: 21517263
Br J Cancer. 1973 Sep;28(3):197-214
pubmed: 4743904
J Epidemiol. 1998 Oct;8(4):235-43
pubmed: 9816815
Oncology. 1984;41(1):36-8
pubmed: 6700933
Int J Epidemiol. 2009 Aug;38(4):978-88
pubmed: 19416955